RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways.
Gagne M, Flynn BJ, Honeycutt CC, Flebbe DR, Andrew SF, Provost SJ, McCormick L, Van Ry A, McCarthy E, Todd JM, Bao S, Teng IT, Marciano S, Rudich Y, Li C, Pessaint L, Dodson A, Cook A, Lewis MG, Andersen H, Zahradník J, Nason MC, Foulds KE, Kwong PD, Roederer M, Schreiber G, Seder RA, Douek DC.
Gagne M, et al. Among authors: li c.
bioRxiv [Preprint]. 2023 Jun 12:2023.06.09.544432. doi: 10.1101/2023.06.09.544432.
bioRxiv. 2023.
PMID: 37503026
Free PMC article.
Preprint.